Dixon Simon R, Whitbourn Robert J, Dae Michael W, Grube Eberhard, Sherman Warren, Schaer Gary L, Jenkins J Stephen, Baim Donald S, Gibbons Raymond J, Kuntz Richard E, Popma Jeffrey J, Nguyen Thanh T, O'Neill William W
Division of Cardiology, William Beaumont Hospital, Royal Oak, Michigan 48073, USA.
J Am Coll Cardiol. 2002 Dec 4;40(11):1928-34. doi: 10.1016/s0735-1097(02)02567-6.
The purpose of this study was to evaluate the safety and feasibility of endovascular cooling during primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI).
In experimental models of AMI, mild systemic hypothermia has been shown to reduce metabolic demand and limit infarct size.
In a multi-center study, 42 patients with AMI (<6 h from symptom onset) were randomized to primary PCI with or without endovascular cooling (target core temperature 33 degrees C). Cooling was maintained for 3 h after reperfusion. Skin warming, oral buspirone, and intravenous meperidine were used to reduce the shivering threshold. The primary end point was major adverse cardiac events at 30 days. Infarct size at 30 days was measured using (99m)Tc-sestamibi SPECT imaging.
Endovascular cooling was performed successfully in 20 patients (95%). All achieved a core temperature below 34 degrees C (mean target temperature 33.2 +/- 0.9 degrees C). The mean temperature at reperfusion was 34.7 +/- 0.9 degrees C. Cooling was well tolerated, with no hemodynamic instability or increase in arrhythmia. Nine patients experienced mild episodic shivering. Major adverse cardiac events occurred in 0% vs. 10% (p = NS) of treated versus control patients. The median infarct size was non-significantly smaller in patients who received cooling compared with the control group (2% vs. 8% of the left ventricle, p = 0.80).
Endovascular cooling can be performed safely as an adjunct to primary PCI for AMI. Further clinical trials are required to determine whether induction of mild systemic hypothermia with endovascular cooling will limit infarct size in patients undergoing reperfusion therapy.
本研究旨在评估急性心肌梗死(AMI)患者在直接经皮冠状动脉介入治疗(PCI)期间进行血管内降温的安全性和可行性。
在AMI的实验模型中,轻度全身性低温已被证明可降低代谢需求并限制梗死面积。
在一项多中心研究中,42例症状发作后<6小时的AMI患者被随机分为接受或不接受血管内降温(目标核心温度33摄氏度)的直接PCI组。再灌注后持续降温3小时。使用皮肤升温、口服丁螺环酮和静脉注射哌替啶来降低寒战阈值。主要终点是30天时的主要不良心脏事件。使用(99m)锝- sestamibi单光子发射计算机断层扫描(SPECT)成像测量30天时的梗死面积。
20例患者(95%)成功进行了血管内降温。所有患者的核心温度均低于34摄氏度(平均目标温度33.2±0.9摄氏度)。再灌注时的平均温度为34.7±0.9摄氏度。降温耐受性良好,未出现血流动力学不稳定或心律失常增加。9例患者出现轻度间歇性寒战。治疗组与对照组患者的主要不良心脏事件发生率分别为0%和10%(p=无显著性差异)。与对照组相比,接受降温治疗的患者梗死面积中位数无显著减小(左心室的2%对8%,p=0.80)。
血管内降温作为AMI直接PCI的辅助手段可安全实施。需要进一步的临床试验来确定血管内降温诱导轻度全身性低温是否会限制接受再灌注治疗患者的梗死面积。